Below are the most recent publications written about "Carcinoma, Renal Cell" by people in Profiles.
-
Khan SY, Snitman A, Habrawi Z, Crawford S, Melkus MW, Layeequr Rahman R. ASO Visual Abstract: The Role of Cryoablation in Breast Cancer Beyond the Oncologic Control: COST and Breast-Q Patient Reported Outcomes. Ann Surg Oncol. 2023 02; 30(2):1040-1041.
-
Molina-Cerrillo J, Santoni M, Ruiz ?, Massari F, Pozas J, Ortego I, G?mez V, Grande E, Alonso-Gordoa T. Epigenetics in advanced renal cell carcinoma: Potential new targets. Crit Rev Oncol Hematol. 2022 Dec; 180:103857.
-
Santoni M, Molina-Cerrillo J, Myint ZW, Massari F, Buchler T, Buti S, Matrana MR, De Giorgi U, Rizzo M, Zabalza IO, Galli L, Zucali PA, Aurilio G, Incorvaia L, Bassanelli M, Mammone G, Salfi A, Isella L, Mollica V, Grande E, Porta C, Battelli N. Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination Therapies. Target Oncol. 2022 09; 17(5):571-581.
-
Santoni M, Massari F, Matrana MR, Basso U, De Giorgi U, Aurilio G, Buti S, Incorvaia L, Rizzo M, Martignetti A, Maslov D, Tawagi K, Philon E, Blake Z, Porta C, Battelli N. Statin use improves the efficacy of nivolumab in patients with advanced renal cell carcinoma. Eur J Cancer. 2022 09; 172:191-198.
-
Santoni M, Monteiro FSM, Massari F, Abahssain H, Aurilio G, Molina-Cerrillo J, Myint ZW, Zabalza IO, Battelli N, Grande E. Statins and renal cell carcinoma: Antitumor activity and influence on cancer risk and survival. Crit Rev Oncol Hematol. 2022 Aug; 176:103731.
-
Rizzo A, Mollica V, Santoni M, Massari F. Assessing PD-L1 status in mRCC treated with first-line immune-based combinations: a?meta-analysis. Immunotherapy. 2022 06; 14(8):617-625.
-
Santoni M, Massari F, Bracarda S, Grande E, Matrana MR, Rizzo M, De Giorgi U, Basso U, Aurilio G, Incorvaia L, Martignetti A, Molina-Cerrillo J, Mollica V, Rizzo A, Battelli N. Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors. Eur Urol Focus. 2022 11; 8(6):1696-1702.
-
Santoni M, Aurilio G, Massari F, Grande E, Matrana MR, Rizzo M, De Giorgi U, Incorvaia L, Martignetti A, Molina-Cerrillo J, Zabalza IO, Mollica V, Rizzo A, Battelli N, Porta C. Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison. Clin Genitourin Cancer. 2022 06; 20(3):285-295.
-
Rizzo A, Mollica V, Santoni M, Rosellini M, Marchetti A, Massari F. Risk of toxicity with immunotherapy-tyrosine kinase inhibitors for metastatic renal cell carcinoma: a meta-analysis of randomized controlled trials. Future Oncol. 2022 Feb; 18(5):625-634.
-
Mollica V, Santoni M, Matrana MR, Basso U, De Giorgi U, Rizzo A, Maruzzo M, Marchetti A, Rosellini M, Bleve S, Maslov D, Tawagi K, Philon E, Blake Z, Massari F. Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma. Target Oncol. 2022 01; 17(1):61-68.